newscost-efficiencyEndometrial Cancer
Selective vs. Universal NGS in Endometrial Cancer: A Cost-Efficiency Breakthrough
By MedXY|Apr 24, 2026
A new study reveals that selective molecular profiling with MMR/p53 IHC followed by NGS for p53-abnormal tumors is more cost-efficient than universal NGS for advanced endometrial cancer, reducing unnecessary testing by 57%.